Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence

Laforest, Laurent; Belhassen, Manon; Devouassoux, Gilles; Didier, A.; Ginoux, M.; Ganse, Éric Van

doi:10.1016/j.jaip.2016.07.008

Cited by 21 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23,24 Previous research has linked adherence with clinical symptoms and outcomes. 4,[25][26][27] However, even in adherent patients, other factors may influence outcomes. For example, inhaler technique is an important determinant of outcome, as it influences the dose of drug delivered to the lungs at each inhalation.…”

Section: Discussionmentioning

confidence: 99%

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Roche

Plaza

Backer³

et al. 2020

npj Prim. Care Respir. Med.

View full text Add to dashboard Cite

Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

show abstract

Section: Discussionmentioning

confidence: 99%

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Roche

Plaza

Backer³

et al. 2020

npj Prim. Care Respir. Med.

View full text Add to dashboard Cite

show abstract

“…The majority of adherence interventions primarily target children with controller medication adherence <80% assuming that children >80% at initial assessment will remain adherent. There is evidence that adherence is not a stable phenomenon (17)(18)(19)(20), although there is a paucity of data on patterns of adherence among individuals with asthma and none within sub-groups of Latino children (21). Souverein et al (17) examined longitudinal patterns of inhaled corticosteroid (ICS) medication initiation (21) among a sample of long term care patients (n=13,922).…”

Section: Abstract Word Count: 350mentioning

confidence: 99%

“…The results identified periods of non-adherence alternating with periods of regular ICS use. LaForest et al (20) examined ICS adherence over 12 months among children and adults selectively recruited for high initial adherence. The investigators noted fragmented episodes of ICS use which typically lasted several months even though all individuals were adherent at baseline (20).…”

Section: Abstract Word Count: 350mentioning

confidence: 99%

“…LaForest et al (20) examined ICS adherence over 12 months among children and adults selectively recruited for high initial adherence. The investigators noted fragmented episodes of ICS use which typically lasted several months even though all individuals were adherent at baseline (20). A better understanding of controller medication adherence patterns in children will provide evidence needed to identify individuals at highest risk for non-adherence and acute healthcare utilization and offer a more intensive intervention while using less-intensive approaches for those at low risk preventing waste of precious healthcare resources.…”

Section: Abstract Word Count: 350mentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal Patterns of Mexican and Puerto Rican Children’s Asthma Controller Medication Adherence and Acute Healthcare Use

Arcoleo¹,

McGovern

Kaur

et al. 2019

Annals ATS

View full text Add to dashboard Cite

CM assisted in conducting the literature review, drafting the Introduction, contributed to the interpretation of data and content of the Conclusions section, and reviewed and provided final approval for the submission. KK was responsible for cleaning the Doser adherence data and variable creation, contributed to the interpretation of data and content of the Conclusions section, and reviewed and provided final approval for the submission. JH provided substantial input on the interpretation of the results, drafting the Introduction and Conclusions sections, and reviewed and provided final approval for the submission. JM participated in drafting the Introduction and Conclusions sections, interpretation of the results and reviewed and provided final approval for the submission. HC assisted KA with the SEM and LLCA analyses, interpretation of the data, and reviewed and provided final approval for the submission. DR participated in drafting the Introduction and Conclusions sections, interpretation of the results, and reviewed and provided final approval for the submission. JF participated in the design of the main study, supervised the cleaning and variable creation from the adherence data, drafting the Introduction and Conclusions sections, interpretation of the results, and reviewed and provided final approval for the submission.

show abstract

“…2 Corticosteroids contribute to control asthma symptoms due to its anti-inflammatory and immunosuppressive effects as a result of the interaction with the glucocorticoid receptor (GR). 45 Nonetheless, many factors such as an incorrect inhaler technique, 46 a poor adherence, 47 comorbidities, 48 lung microbiome dysbiosis, [49][50][51][52] and genetic variants, 13,17 may contribute to a loss in asthma control and to the development of asthma exacerbations despite ICScontained therapies. The identification of these factors is essential to differentiate children with difficult-to-treat asthma from those that are resistant to pharmacological therapies.…”

Section: Inhaled Corticosteroids (Ics)mentioning

confidence: 99%

<p>Pharmacogenetics of Pediatric Asthma: Current Perspectives</p>

Pérez-García¹,

Espuela‐Ortiz²,

Lorenzo-Díaz³

et al. 2020

PGPM

View full text Add to dashboard Cite

Asthma is a chronic respiratory disease that affects 339 million people worldwide and has a considerable impact on the pediatric population. Asthma symptoms can be controlled by pharmacological treatment. However, some patients do not respond to therapy and continue suffering from symptoms, which impair the quality of life of patients and limit their daily activity. Genetic variation has been shown to have a role in treatment response. The aim of this review is to update the main findings described in pharmacogenetic studies of pediatric asthma published from

show abstract

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence

Cited by 21 publications

References 42 publications

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)

Longitudinal Patterns of Mexican and Puerto Rican Children’s Asthma Controller Medication Adherence and Acute Healthcare Use

<p>Pharmacogenetics of Pediatric Asthma: Current Perspectives</p>

Contact Info

Product

Resources

About